EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab

Takahito Awatsu, Toru Kadono, Hirokazu Shoji, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Atsuo Takashima, Akihito Nagahara, Ken Kato

Anticancer Research · 2026

DOI: 10.21873/anticanres.18006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Takahito Awatsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Claudins. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsCell Adhesion MoleculesAntigens, NeoplasmClaudinsNivolumabAntineoplastic Agents, ImmunologicalHumansFemalePrognosisMaleMiddle AgedAgedRetrospective StudiesAdultBiomarkers, TumorAged, 80 and over

Stichwörter der Autor:innen

CLDN18.2Gastric cancerTROP2nivolumab

Substanzen

TACSTD2 protein, humanCell Adhesion MoleculesAntigens, NeoplasmClaudinsNivolumabAntineoplastic Agents, ImmunologicalCLDN18 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; hshouji@ncc.go.jp.
  • Department of Pathophysiological Research and Therapeutics for Gastrointestinal Disease, Juntendo University Faculty of Medicine, Tokyo, Japan.

Zitieren

APA

Awatsu, T., Kadono, T., Shoji, H., Hirose, T., Hirano, H., Okita, N., Takashima, A., Nagahara, A., & Kato, K. (2026). Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab. Anticancer Research. https://doi.org/10.21873/anticanres.18006

Vancouver

Awatsu T, Kadono T, Shoji H, Hirose T, Hirano H, Okita N, et al. Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab. Anticancer Research. 2026. doi:10.21873/anticanres.18006

BibTeX
@article{Awatsu2026,
  author = {Awatsu, Takahito and Kadono, Toru and Shoji, Hirokazu and Hirose, Toshiharu and Hirano, Hidekazu and Okita, Natsuko and Takashima, Atsuo and Nagahara, Akihito and Kato, Ken},
  title = {Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18006}
}
Kostenlos starten →